Faxeladol

Faxeladol
Clinical data
Other names	Faxeladol
ATC code	None;
Identifiers
	IUPAC name 3-[(1R,2R)-2-dimethylaminomethylcyclohexyl]phenol;
CAS Number	433265-65-7 ;
PubChem CID	9813414;
ChemSpider	7989164 ;
UNII	C04V6SGK8H;
KEGG	D10007 ;
CompTox Dashboard (EPA)	DTXSID20912318 ;
Chemical and physical data
Formula	C15H23NO
Molar mass	233.355 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1cccc(c1)[C@@H]2CCCC[C@H]2CN(C)C;
	InChI InChI=1S/C15H23NO/c1-16(2)11-13-6-3-4-9-15(13)12-7-5-8-14(17)10-12/h5,7-8,10,13,15,17H,3-4,6,9,11H2,1-2H3/t13-,15-/m0/s1 ; Key:JIRYWFYYBBRJAN-ZFWWWQNUSA-N ;
	(what is this?) (verify)

Faxeladol (INN, USAN) (code names GRTA-9906, GRTA-0009906, EM-906, GCR-9905, GRT-TA300) is an opioid analgesic which was developed by Grünenthal GmbH but was never marketed for medical use anywhere in the world. It is related to tramadol and ciramadol, and was developed shortly after tramadol in the late 1970s. Similarly to tramadol, it was believed faxeladol would have analgesic, as well as antidepressant effects, due to its action on serotonin and norepinephrine reuptake. In various studies in the 1970s alongside tramadol, faxeladol was seen to be slightly more potent than tramadol, but with a higher rate of sudden seizures than tramadol, which is known to cause seizures without warning in some users.

References

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Faxeladol

See also

References